This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Under the Radar: Stericycle Dumps Rivals

Stocks in this article: SRCLWMI

"Under the Radar" is a daily feature that uncovers little-known companies worthy of investors' consideration. Check in at 5 every morning to find out about stocks that tend to beat their bigger brethren.

The ideal stock offers three things: a compelling story, a margin of safety and a low price. In the case of Lake Forest, Ill.-based Stericycle (SRCL), two out of three ain't bad.

TheStreet.com Ratings

In the summer of 1987, swimmers on the Jersey Shore and Long Island were alarmed as medical waste, including blood vials and syringes, bobbed in the waves and washed ashore. It was clear that more stringent medical-waste regulation was necessary and, in 1988, Congress passed the Medical Waste Tracking Act, which initially required medical waste to be incinerated. Shortly thereafter, Stericycle was founded.

Since its inception, the company has pursued aggressive growth by undercutting competitors, securing long-term contracts and, in 1993, adopting an acquisition strategy. Stericycle has completed 157 acquisitions, including 114 in the U.S. and 43 internationally. The company hopes to keep growing its leading market share in the medical waste disposal industry and outshine rival Waste Management (WMI).

Stericycle is thriving. It not only offers disposal services, but advises hospitals and doctors' offices on how to properly reduce and store medical waste in compliance with federal and state laws. The company's first-quarter revenue climbed 8.8% to $255 million, as net income jumped 28% to $41 million and earnings per share climbed 34% to 47 cents.

I am less than thrilled about the company's balance sheet, which holds $724 million of long-term debt, $8 million in interest expenses and just $12 million of cash. Stericycle has to fuel its growth somehow, and recent acquisitions have been well-integrated. Still, a healthier cash balance and lower debt burden should be long-term financial goals.

Unfortunately, investors have recognized the company's strengths and, consequently, its stock trades at a high level. Stericycle has a price-to-earnings ratio of about 29, indicating a premium to its average peer and the overall market. But the high cost is justifiable, if you consider the company's growth potential and recent returns. The stock has doubled four times since the company went public in 1996.

The Street.com Ratings gives Stericycle a "buy" recommendation.

TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs